{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T23:22:13Z","timestamp":1781306533214,"version":"3.54.1"},"reference-count":30,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"University of Chicago Comprehensive Cancer Center","award":["IIT Grant"],"award-info":[{"award-number":["IIT Grant"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Prostate cancer (PCa) is one of the most commonly diagnosed cancers. Treatments for PCa with less adverse effects than whole gland interventions, such as focal therapy (FT), often involve a higher risk of PCa recurrence. Combining FT with other treatments could increase the efficacy while maintaining a low side effect profile. This study aims to determine the proportion of residual\/recurrent clinically significant PCa following the combination treatment of three months of androgen deprivation therapy (ADT) and FT of the prostate, as well as the safety of this treatment regimen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study will be a single arm phase II trial with a recruitment goal of 57 patients with treatment na\u00efve non-metastatic intermediate risk PCa. Patients will complete the I-PSS, SHIM, and EPIC-26 questionnaires at the screening visit. Patients will then comply with a three-month treatment course of ADT. Eight weeks after beginning ADT, patients will undergo FT of the prostate via high intensity focused ultrasound or cryoablation. Follow up visits will occur every three months for a year post FT to monitor for side effects, repeat questionnaires, perform a clinical assessment, and obtain PSA and testosterone values. Twelve months after FT, a surveillance multiparametric MRI and MRI-targeted biopsy will be performed to assess for treatment failure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The primary endpoint of this trial is to determine the proportion of men with clinically significant PCa as evaluated by a surveillance mpMRI and MRI-TB at 12-months following FT. If successful, this treatment approach could offer a new option for treatment with fewer side effects than whole gland interventions and more efficacy than FT alone. Furthermore it could inform the need for further research into multimodal treatment options for PCa.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Clinical trial registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov, NCT05790213. Registered on March 30, 2023.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0337828","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T18:27:17Z","timestamp":1765909637000},"page":"e0337828","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Phase II trial protocol of focal prostate ablation combined with androgen deprivation therapy for prostate cancer treatment"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4533-3813","authenticated-orcid":true,"given":"Jason","family":"Koehler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Lama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Mendez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7822-0826","authenticated-orcid":true,"given":"Wei-Wen","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aytekin","family":"Oto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell","family":"Szmulewitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3197-7215","authenticated-orcid":true,"given":"Abhinav","family":"Sidana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,12,16]]},"reference":[{"key":"pone.0337828.ref001","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1200\/JCO.2018.36.6_suppl.130","article-title":"Which patients with localized prostate cancer account for the greatest proportion of prostate cancer deaths?","volume":"36","author":"M Nezolosky","year":"2018","journal-title":"J Clin Oncol"},{"issue":"5","key":"pone.0337828.ref002","doi-asserted-by":"crossref","first-page":"479","DOI":"10.6004\/jnccn.2019.0023","article-title":"Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology","volume":"17","author":"JL Mohler","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"pone.0337828.ref003","doi-asserted-by":"crossref","first-page":"59","DOI":"10.4103\/iju.iju_239_24","article-title":"Shifting tides: A survey analysis of urologists\u2019 evolving attitudes toward focal therapy for prostate cancer","volume":"41","author":"J Koehler","year":"2025","journal-title":"Indian J Urol"},{"key":"pone.0337828.ref004","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.urology.2007.06.001","article-title":"\u201cMale lumpectomy\u201d: focal therapy for prostate cancer using cryoablation","volume":"70","author":"G Onik","year":"2007","journal-title":"Urology"},{"issue":"3","key":"pone.0337828.ref005","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2024.11.009","article-title":"Prostate ablation for the management of localized prostate cancer","volume":"43","author":"A Sidana","year":"2025","journal-title":"Urol Oncol"},{"issue":"5","key":"pone.0337828.ref006","first-page":"313","article-title":"Mechanisms of tissue destruction following cryosurgery","volume":"66","author":"DK Whittaker","year":"1984","journal-title":"Ann R Coll Surg Engl"},{"key":"pone.0337828.ref007","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0090-4295(02)01683-7","article-title":"The cryobiology of cryosurgical injury","volume":"60","author":"NE Hoffmann","year":"2002","journal-title":"Urology"},{"issue":"11","key":"pone.0337828.ref008","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1007\/s00345-016-1811-9","article-title":"Focal salvage therapy for local prostate cancer recurrences after primary radiotherapy: a comprehensive review","volume":"34","author":"DAS Duijzentkunst","year":"2016","journal-title":"World J Urol"},{"issue":"4","key":"pone.0337828.ref009","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.eururo.2013.05.048","article-title":"The role of focal therapy in the management of localised prostate cancer: a systematic review","volume":"66","author":"M Valerio","year":"2014","journal-title":"Eur Urol"},{"issue":"5","key":"pone.0337828.ref010","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2024.01.003","article-title":"Magnetic resonance imaging-ultrasound fusion guided focal cryoablation for men with intermediate-risk prostate cancer","volume":"42","author":"A Sidana","year":"2024","journal-title":"Urol Oncol"},{"issue":"1","key":"pone.0337828.ref011","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.eururo.2018.12.030","article-title":"Early-Medium-Term Outcomes of Primary Focal Cryotherapy to Treat Nonmetastatic Clinically Significant Prostate Cancer from a Prospective Multicentre Registry","volume":"76","author":"TT Shah","year":"2019","journal-title":"Eur Urol"},{"issue":"3","key":"pone.0337828.ref012","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/CCO.0000000000000515","article-title":"Contemporary treatments in prostate cancer focal therapy","volume":"31","author":"M Ahdoot","year":"2019","journal-title":"Curr Opin Oncol"},{"issue":"7","key":"pone.0337828.ref013","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/S1470-2045(22)00251-0","article-title":"MRI-guided focused ultrasound focal therapy for patients with intermediate-risk prostate cancer: a phase 2b, multicentre study","volume":"23","author":"B Ehdaie","year":"2022","journal-title":"Lancet Oncol"},{"issue":"10","key":"pone.0337828.ref014","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/nrurol.2010.142","article-title":"Focal therapy in prostate cancer: modalities, findings and future considerations","volume":"7","author":"U Lindner","year":"2010","journal-title":"Nat Rev Urol"},{"issue":"6","key":"pone.0337828.ref015","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S1470-2045(12)70121-3","article-title":"Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study","volume":"13","author":"HU Ahmed","year":"2012","journal-title":"Lancet Oncol"},{"issue":"3","key":"pone.0337828.ref016","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1148\/radiol.2463062080","article-title":"MR imaging of prostate after treatment with high-intensity focused ultrasound","volume":"246","author":"APS Kirkham","year":"2008","journal-title":"Radiology"},{"issue":"3","key":"pone.0337828.ref017","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/bju.14710","article-title":"Medium-term oncological outcomes in a large cohort of men treated with either focal or hemi-ablation using high-intensity focused ultrasonography for primary localized prostate cancer","volume":"124","author":"A Stabile","year":"2019","journal-title":"BJU Int"},{"issue":"2","key":"pone.0337828.ref018","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1590\/s1677-5538.ibju.2017.0025","article-title":"High-intensity Focused Ultrasound (HIFU) as salvage therapy for radio-recurrent prostate cancer: predictors of disease response","volume":"44","author":"S Dason","year":"2018","journal-title":"Int Braz J Urol"},{"key":"pone.0337828.ref019","doi-asserted-by":"crossref","first-page":"705025","DOI":"10.3389\/fonc.2021.705025","article-title":"The Use of High-Intensity Focused Ultrasound (HIFU) Plus 150mg Bicalutamide as First Line Salvage Therapy for Local Recurrent Prostate Cancer","volume":"11","author":"J-Z Cao","year":"2021","journal-title":"Front Oncol"},{"issue":"8","key":"pone.0337828.ref020","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.3390\/cancers17081337","article-title":"Surveillance After Focal Therapy for Prostate Cancer: A Comprehensive Review","volume":"17","author":"J Koehler","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"41","key":"pone.0337828.ref021","article-title":"The primary treatment of prostate cancer with high-intensity focused ultrasound: A systematic review and meta-analysis","volume":"99","author":"Y He","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"pone.0337828.ref022","first-page":"293","article-title":"Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate.","volume":"1","author":"C Huggins","year":"1941","journal-title":"Cancer Res"},{"issue":"11","key":"pone.0337828.ref023","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1517\/13543784.16.11.1851","article-title":"Leuprolide acetate: a drug of diverse clinical applications","volume":"16","author":"AC Wilson","year":"2007","journal-title":"Expert Opin Investig Drugs"},{"issue":"6","key":"pone.0337828.ref024","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1097\/JU.0000000000003452","article-title":"Updates to Advanced Prostate Cancer: AUA\/SUO Guideline (2023)","volume":"209","author":"W Lowrance","year":"2023","journal-title":"J Urol"},{"issue":"9327","key":"pone.0337828.ref025","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0140-6736(02)09408-4","article-title":"Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial","volume":"360","author":"M Bolla","year":"2002","journal-title":"Lancet"},{"issue":"2","key":"pone.0337828.ref026","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/cncr.24779","article-title":"A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer","volume":"116","author":"BJ Donnelly","year":"2010","journal-title":"Cancer"},{"issue":"1","key":"pone.0337828.ref027","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/sj.pcan.4500988","article-title":"Randomized trial comparing cryoablation and external beam radiotherapy for T2C-T3B prostate cancer","volume":"11","author":"JL Chin","year":"2008","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"2","key":"pone.0337828.ref028","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.ijrobp.2021.08.031","article-title":"Adding Short-Term Androgen Deprivation Therapy to Radiation Therapy in Men With Localized Prostate Cancer: Long-Term Update of the NRG\/RTOG 9408 Randomized Clinical Trial","volume":"112","author":"CU Jones","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"pone.0337828.ref029","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S1470-2045(15)00011-X","article-title":"Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial","volume":"16","author":"K Fizazi","year":"2015","journal-title":"Lancet Oncol"},{"issue":"3","key":"pone.0337828.ref030","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S1470-2045(24)00730-7","article-title":"ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial","volume":"26","author":"G Marvaso","year":"2025","journal-title":"Lancet Oncol"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0337828","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T18:27:22Z","timestamp":1765909642000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0337828"}},"subtitle":[],"editor":[{"given":"Ebenezer","family":"Wiafe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,12,16]]},"references-count":30,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0337828","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,16]]}}}